Block listing Interim Review
Delignit AG
€3.28
18:34 28/03/24
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 25 July 2019
Name of applicant: | Next plc | |||
Name of scheme: | The Next Long Term Incentive Plan (formerly known as The Next 2006 Performance Share Plan) | |||
Period of return: | From: | 26.01.19 | To: | 25.07.19 |
Balance of unallotted securities under scheme(s) from previous return: | 278,729 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | N/A | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | N/A | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 278,729 | |||
Name of contact: | Ms Seonna Anderson |
Telephone number of contact: | 0116 284 2170 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 25 July 2019
Name of applicant: | Next plc | |||
Name of scheme: | Next plc 2010 Share Matching Plan | |||
Period of return: | From: | 26.01.19 | To: | 25.07.19 |
Balance of unallotted securities under scheme(s) from previous return: | 250,000 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | N/A | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | N/A | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 250,000 | |||
Name of contact: | Ms Seonna Anderson |
Telephone number of contact: | 0116 284 2170 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.